نتایج جستجو برای: novoseven

تعداد نتایج: 115  

2011

Haemophiliacs A patients treated with FVIII concentrates from human or recombinant origin may develop inhibitors, the most frequent complication leading to increased morbidity and mortality. These patients cannot be treated with usual FVIII concentrates, and bleeding episodes require the use of a bypassing coagulant therapy (such as Novoseven®). Identification and quantitation of those antibodi...

Journal: :Thrombosis and haemostasis 1998
A D Shapiro G S Gilchrist W K Hoots H A Cooper D A Gastineau

Recombinant factor VIIa (rFVIIa: NovoSeven; Novo Nordisk) has proven efficacy in the treatment of haemophilic patients with inhibitors. This prospective, double-blind study compared rFVIIa (35 vs. 90 microg/kg) in the initiation and maintenance of haemostasis during and after elective surgery. Patients with inhibitors (FVIII, n = 26; FIX, n = 3) received rFVIIa immediately prior to incision; in...

2015
Naveen Pemmaraju Koji Sasaki Daniel Johnson Naval Daver Vahid Afshar-Kharghan Merry Chen Sairah Ahmed Rivka R. Colen Michael Kwon Yang Huh Gautam Borthakur

Intracranial hemorrhage (ICH) is a common complication in acute myeloid leukemia (AML) patients with an incidence rate of 6.3% (1). Bleeding disorders related to disseminated intravascular coagulation (DIC) are common complications in AML cases (2). Recombinant activated Factor VII [rFVIIa (NovoSeven(®))] is approved for the treatment of bleeding complications with FVIII or FIX inhibitors in pa...

Journal: :International journal of hematology 2006
Massimo Franchini

Recombinant activated factor VII (rFVIIa) (NovoSeven) is a novel hemostatic agent originally developed to treat bleeding episodes in hemophilic patients with inhibitors against coagulation factors VIII and IX. In recent years, rFVIIa has also been employed for the management of uncontrolled bleeding in a number of congenital and acquired hemostatic abnormalities. Based on a literature search in...

2010
Won Seok Lee Young Sil Park

Congenital factor VII deficiency is a rare autosomal-recessive bleeding disorder. Bleeding manifestations and clinical findings vary widely, ranging from asymptomatic subjects to patients with hemorrhages that may cause significant handicaps. Treatment has traditionally involved factor VII(FVII) replacement therapy using fresh frozen plasma, prothrombin complex concentrates or plasma-derived FV...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید